Maria G. Cardona‐Gonzalez, Jason D. Goldman, Lawrence Narayan, Diana M. Brainard, Kris V. Kowdley – 14 November 2018 – There are limited data on direct‐acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.

This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.Michael W. Fried (Moderator) Arun J. Sanyal Arun J.

This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.Jorge A. Bezerra (Moderator) Mary E. McCarthy Rinella Mary E. Rinella, MD is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program.

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Jorge A. Bezerra (Moderator) Jordan J. Feld Jordan J. Feld, MD, MPH, FAASLD attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis.

This session provides a summary of the clinical highlights from The Liver Meeting®.Jorge A. Bezerra (Moderator) K. Rajender Reddy

Babak Torabi Sagvand, Katelyn Edwards, Bo Shen – 13 November 2018 – The prevalence polyps (GBPs) in the general population has been estimated to be approximately 5%, with up to 10% of these being dysplastic or malignant. Previous studies have suggested that patients with primary sclerosing cholangitis (PSC) have increased frequency of GBPs. However, data on the prevalence, risk factors, and outcome of GBPs in these patients are sparse. This case‐control study investigates the frequency, risk factors, and outcome of GBPs in patients with PSC.

HCC is the fifth most common cancer and the third cause of cancer-related deaths worldwide. The underlying liver disease that ultimately leads to HCC varies throughout the world. Identifying the population at risk for HCC is critical in order to implement preventive strategies to reduce the burden of the disease. Moreover, identifying the population at risk will facilitate the use of surveillance programs.

Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for  monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.Mark I.

This program aims to help attendees understand how to best approach the patient referred for evaluation of an incidentally found liver mass, be better informed on how to conduct office-based noninvasive assessment of liver fibrosis in the patient with elevated liver tests, increase their understanding of the management of alcoholic liver disease in 2018 and have the knowledge to provide care in the post-liver transplant patient in the community setting.K. Rajender Reddy Marcelo Kugelmas Craig J. McClain Kirti Shetty

This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding  screening issues for patients with cirrhosis will be reviewed.Michael B. Fallon Michael B. Fallon, MD, FAASLD is Professor and Chair of the Department of Medicine at the University of Arizona College of Medicine – Phoenix (UACOMP).